Table 1.
Patient characteristics
|
ID |
Age |
Primary tumor |
Recurrence |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Recurrence | Inclusion | Type | FIGO stage | Treatment | Chemotherapy | Region | Interval prim-rec (months) | Treatment | Chemotype | Interval Chemo-1st Vac (months) | |
| 1 |
40 |
41 |
41 |
cervix |
IB1 |
RH/CHRT |
Cisplatin |
LR |
14 |
|
|
12.0 |
| 2 |
49 |
51 |
51 |
cervix |
IIB |
CHRT |
Cisplatin |
D |
26 |
|
|
33.3 |
| 3 |
43 |
46 |
46 |
cervix |
IB1 |
RH/RT |
|
D |
37 |
|
|
|
| 4 |
34 |
35 |
36 |
cervix |
IB2 |
CHRT/RH |
Cisplatin |
D |
18 |
|
|
17.1 |
| 5 |
30 |
30 |
30 |
cervix |
IB1 |
RH/CHRT |
Cisplatin |
LR |
6 |
|
|
5.3 |
| 6 |
55 |
56 |
56 |
cervix |
IIIB |
CHRT |
UK |
D |
3 |
|
|
3.9 |
| 7 |
51 |
52 |
53 |
vagina |
IVB |
CHRT |
Carboplatin/Taxol |
D |
16 |
RT |
|
19.6 |
| 8 |
34 |
36 |
36 |
cervix |
IB1 |
RH/RT |
|
D |
19 |
CH |
Cisplatin/Topotecan |
1.8 |
| 9 |
54 |
56 |
56 |
vagina |
IIB |
CHRT |
Cisplatin |
D |
20 |
RT + HT |
|
22.9 |
| 10 |
38 |
45 |
46 |
anus |
|
CHRT |
UK |
LR |
79 |
CHRT |
UK |
41.9 |
| 11 |
44 |
46 |
46 |
cervix |
IIIB |
CHRT |
Cisplatin |
D |
6 |
|
|
4.9 |
| 12 |
36 |
40 |
41 |
cervix |
IIA |
RH/CHRT |
Cisplatin |
D |
40 |
HT + CH |
Carboplatin/Taxol |
4.4 |
| 13 |
62 |
63 |
63 |
cervix |
IV |
RH/CHRT |
Cisplatin |
D |
11 |
|
|
7.9 |
| 14 |
32 |
32 |
32 |
cervix |
IIB |
CHRT |
Cisplatin |
D |
8 |
|
|
7.5 |
| 15 |
35 |
36 |
36 |
cervix |
IB1 |
SN/CHRT |
Cisplatin |
LR |
4 |
SUR |
|
4.3 |
| 16 |
54 |
54 |
54 |
cervix |
IV |
|
|
|
|
|
|
|
| 17 |
48 |
49 |
50 |
cervix |
IIB |
SUR |
|
D |
9 |
|
|
|
| 18 |
58 |
59 |
59 |
cervix |
IB2 |
CHRT/RH |
Cisplatin |
D |
11 |
RT |
|
|
| 19 |
52 |
54 |
54 |
cervix |
IIA |
CHRT |
Carboplatin/Cisplatin |
LR |
31 |
|
|
37.4 |
| 20 |
39 |
40 |
41 |
cervix |
IB1 |
RH |
|
D |
14 |
CHRT + CH |
Carboplatin/Taxol |
2.2 |
| 21 | 46 | 47 | 47 | anus | CH | Cisplatin/Vinorelbine | 4 | 6.5 | ||||
LR, locoregional; D, distant metastasis; RH, radical hysterectomy; CH, chemotherapy; CHRT, chemoradiation; RT, radiotherapy; SN, Sentinal Node Procedure; HT, hyperthermia; SUR, surgery; UK, unknown; FIGO, International Federation of Gynecologists and Obstetricians. FIGO stage IB1 (clinical lesion ≤ 4 cm) and IB2 (clinical lesion > 4 cm) confined to the cervix. Stage II: tumor extension beyond the cervix, but not the distal 1/3 part of the vagina or the pelvic wall (stage IIA: involvement of the proximal 2/3 part of the vagina, stage IIB: parametrial involvement). Stage IIIB, carcinoma has extended to the pelvic wall and/or the distal 1/3 part of the vagina, and/or causes hydronefrosis. Stage IV, carcinomas spread to the mucosa of the bladder or rectum (stage IV A) or distant organs (stage IVB). The interval between the primary tumor and recurrence (prim-rec) is given in months. The interval between the chemotherapy and the 1st vaccination (Chemo-1st Vac) was calculated by using the starting date of the last given chemotherapy and the date of first vaccination as reference points.